Show simple item record

dc.contributor.authorWeir, Matthew R
dc.contributor.authorSlee, April
dc.contributor.authorSun, Tao
dc.contributor.authorBalis, Dainius
dc.contributor.authorOh, Richard
dc.contributor.authorde Zeeuw, Dick
dc.contributor.authorPerkovic, Vlado
dc.date.accessioned2021-07-07T16:36:57Z
dc.date.available2021-07-07T16:36:57Z
dc.date.issued2020-09-02
dc.identifier.urihttp://hdl.handle.net/10713/16141
dc.description.abstractBackground: Hyperkalemia is a modifiable risk factor for sudden cardiac death, a leading cause of mortality in hemodialysis patients. The optimal treatment of hyperkalemia in hospitalized end stage renal disease (ESRD) patients is nonexsistent in literature which has prompted studies from outpatient dialysis to be extrapolated to inpatient care. The goal of this study was to determine if low potassium dialysate 1 meq/L is associated with higher mortality in hospitalized ESRD patients with severe hyperkalemia (serum potassium > 6.5 mmol/L). Methods: We conducted a retrospective study of all adult ESRD patients admitted with severe hyperkalemia between January 2011- August 2016. Results: There were 209 ESRD patients on hemodialysis admitted with severe hyperkalemia during the study period. Mean serum potassium was 7.1 mmol/L. In-hospital mortality or cardiac arrest in ESRD patients with severe hyperkalemia was 12.4%. Median time to dialysis after serum potassium result was 2.0 hours (25, 75 IQR 0.9, 4.2 hours). 47.4% of patients received dialysis with 1mEq/L concentration potassium bath. The use of 1mEq/L potassium bath was associated with significantly lower mortality or cardiac arrest in ESRD patients admitted with severe hyperkalemia (OR 0.27 95% C.I. 0.09-0.80, p = 0.01). Conclusion: We conclude that use of 1mEq/L potassium bath for treatment of severe hyperkalemia (>6.5 mmol/L) in hospitalized ESRD patients is associated with decreased in-hospital mortality or cardiac arrest.en_US
dc.description.urihttps://doi.org/10.1093/ckj/sfaa133en_US
dc.description.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/pmc8247742/en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofClinical Kidney Journalen_US
dc.rights© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.en_US
dc.subjectSGLT2 inhibitoren_US
dc.subjectType 2 diabetesen_US
dc.subjectcanagliflozinen_US
dc.subjecthyperkalemiaen_US
dc.subjectpotassiumen_US
dc.titleEffects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Programen_US
dc.typeArticleen_US
dc.identifier.doi10.1093/ckj/sfaa133
dc.identifier.pmid34221371
dc.source.volume14
dc.source.issue5
dc.source.beginpage1396
dc.source.endpage1402
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record